SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

ABSTRACT:

Background

SHON nuclear expression (SHON-Nuc⁺) was previously reported to predict clinical outcomes to tamoxifen therapy in ERα⁺ breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a more accurate prediction and serve as a biomarker for anthracycline-based combination chemotherapy (ACT).

Methods

SHON expression was determined by immunohistochemistry in the Nottingham early-stage-BC cohort (n = 1,650) who, if eligible, received adjuvant tamoxifen; the Nottingham ERα^- early-stage-BC (n = 697) patients who received adjuvant ACT; and the Nottingham locally advanced-BC cohort who received pre-operative ACT with/without taxanes (Neo-ACT, n = 120) and if eligible, 5-year adjuvant tamox

SUBMITTER: Abdel-Fatah TMA 

PROVIDER: S-EPMC6461947 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature